Search Results

You are looking at 71 - 80 of 576 items for :

  • Refine by Access: All x
Clear All
Full access

HSR19-091: Incidence of Adverse Events Following Use of Different PARP Inhibitors: Systematic Review and Meta-Analysis

Thanh Ho, Irbaz Bin Riaz, Maheen Akhter, Saad Ullah Malik, Anum Riaz, Muhammad Zain Farooq, Safi U. Khan, Zhen Wang, M. Hassan Murad, and Andrea Wahner Hendrickson

). Of 1,685 patients who received PARPi, incidence of any AE, regardless of grade, was 98.5% (95% CI, 97.2–99.2%). Common AEs were: nausea (incidence rate, 68.9% and 95% CI, 58.7%–77.5%), fatigue (56.3%, 45.3%–66.8%), anemia (46.3%, 37

Full access

HSR19-108: A Meta-Analysis of Randomized Controlled Trials (RCTs) for Efficacy and Safety of Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors (VEGF-TKIs) Adjuvant Therapy in High-Risk Renal Cell Cancer (RCC)

Irbaz Bin Riaz, Saad Ullah Malik, Muhammad Husnain, Qurat Ul Ain Riaz Sipra, Warda Faridi, Farva R. Gondal, Thanh Ho, Siddhartha Yadav, Zhen Wang, and Manish Kohli

.90; 95% CI, 0.67–1.19). Use of TKIs was associated with significantly increased risk of drug toxicity. Increased risk of grade 3 or 4 adverse events (RR=5.110; 95% CI, 3.765–6.935), diarrhea (RR=10.725; 95% CI, 4.672–24.622), fatigue (RR=3.310; 95% CI, 1

Full access

HSR19-112: Qualitative Development of a Patient-Reported Outcome Measure of Symptom Burden in Breast Cancer

Meagan S. Whisenant, Faith A. Strunk, Debasish Tripathy, and Loretta A. Williams

. Fatigue and distress were described by most women regardless of treatment, whereas arm swelling was reported only by women who had undergone surgery, and skin changes were reported primarily by women who received radiation therapy. Patients volunteered

Full access

CLO19-031: Immune Checkpoint Inhibitors: Optimization of Pharmacy Services in Toxicity Management

Olivia G. Fahey, Elizabeth N. Dow, Jennifer K. Piccolo, and Ticiana A. Leal

pharmacists were gastrointestinal (n=15) and dermatologic (n=6). Endocrine (n=7) and dermatologic (n=7) were the most common grade 1 or 2 irAEs identified by other providers. There were 4 grade 3 irAEs (endocrine, fatigue, liver, and pneumonitis) identified by

Full access

CLO19-029: Dosing Patterns of Nilotinib Use in SIMPLICITY, an Observational Study in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients (Pts) in Routine Clinical Practice

Jorge Cortes, Clara Chen, Michael Mauro, Neela Kumar, Catherine Davis, and Stuart L. Goldberg

baseline fatigue (OR=1.799; P =0.072). Conclusions: Most pts treated with 1L NIL were started on 300 or 400 mg (BID); however, 1 in 4 pts required a dose reduction, most often due to intolerance. Physicians at academic centers were more likely to reduce

Full access

Outcomes From a Patient-Centered, Interprofessional, Palliative Consult Team in Oncology

Andrea Feldstain, Barry D. Bultz, Janet de Groot, Amane Abdul-Razzak, Leonie Herx, Lyle Galloway, Srini Chary, and Aynharan Sinnarajah

study can be found on the Alberta Health Services website. 11 Edmonton Symptom Assessment System: The ESAS 12 is a self-report questionnaire that asks patients to rate the severity of their current suffering regarding 9 common symptoms (pain, fatigue

Full access

Do All Patients With Polycythemia Vera or Essential Thrombocythemia Need Cytoreduction?

Kamya Sankar and Brady L. Stein

provided molecular targets for drug development in both PV and ET. The primary goals of treatment for MPNs are to reduce the risk of thrombosis and alleviate systemic symptom burden (eg, fatigue, pruritus, microvascular symptoms, symptomatic splenomegaly

Full access

Personalizing Medicine Through Personalized Communication: Individuality of the Patient Across Borders and Cultures

Giuseppe Curigliano

in all geo-cultural groups are particularly traumatized by the overt physical changes from breast cancer treatments. The stigmata of breast surgery and of treatment-related side effects such as hair loss and fatigue confirm to women the reality of

Full access

Are We on the Same Page? Patient and Provider Perceptions About Exercise in Cancer Care: A Focus Group Study

Agnes Smaradottir, Angela L. Smith, Andrew J. Borgert, and Kurt R. Oettel

mentioned fatigue most often as a significant barrier to exercise (50%). Other barriers included symptoms of disease, such as dyspnea, pain, and impaired mobility. Side effects of treatment, including nausea, vomiting, diarrhea, neuropathic pain, emotional

Full access

Impact of Exercise on Chemotherapy Tolerance and Survival in Early-Stage Breast Cancer: A Nonrandomized Controlled Trial

Amy A. Kirkham, Karen A. Gelmon, Cheri L. Van Patten, Kelcey A. Bland, Holly Wollmann, Donald C. McKenzie, Taryne Landry, and Kristin L. Campbell

survival. 1 Proposed mechanisms for this positive effect on chemotherapy treatment tolerance include exercise-related amelioration of specific symptoms or toxicities that cause treatment reductions or delays, including neutropenia, fatigue, and neuropathy